首页> 外文期刊>Therapeutic advances in respiratory disease. >A review of therapeutic agents for the management of pulmonary arterial hypertension
【24h】

A review of therapeutic agents for the management of pulmonary arterial hypertension

机译:治疗肺动脉高压的治疗药物综述

获取原文
           

摘要

Pulmonary arterial hypertension (PAH) is an uncommon, progressive and life threatening disease characterized by a proliferative vasculopathy of the small muscular pulmonary arterioles resulting in elevated pulmonary vascular resistance and eventually right ventricular failure. An increasing understanding of the pathobiology of PAH and its natural history has led to the development of numerous targeted therapies. Despite these advances there is significant progression of disease and the survival rate remains low. This article reviews the agents currently available for the medical management of PAH.
机译:肺动脉高压(PAH)是一种罕见,进行性和危及生命的疾病,其特征为小肌肉性肺小动脉增生性血管病变,导致肺血管阻力增加,最终导致右心室衰竭。对PAH的病理生物学及其自然历史的日益了解导致了许多靶向疗法的发展。尽管取得了这些进展,但疾病仍显着进展,存活率仍然很低。本文介绍了当前可用于PAH医疗管理的代理商。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号